9 results about "Dicaffeoylquinic acid" patented technology

The present invention relates to an anti-glycosylation composition for improving pores, improving skin barrier, improving wrinkles and resisting glycosylation, containing an artichoke extract in which 1, 5-dicaffeoylquinic acid and chlorogenic acid are increased. According to the artichoke, the state that the content of 1, 5-dicaffeoylquinic acid and chlorogenic acid in the extract is increased through raw material pretreatment engineering is achieved, and the pore size reducing effect and the sebum adjusting effect of the extract are remarkably improved; in addition, various skin health improving effects, skin barrier improving effects and the like, which are obtained by anti-glycosylation effects, are more excellent than those of the conventional artichoke extract, thereby exhibiting suitability of a highly functional cosmetic composition which can improve sensitivity and complex skin.

This invention provides a method for extracting active ingredients from *Erigeron breviscapus*, belonging to the field of pharmaceutical technology. Based on the differences in the physicochemical properties of the compounds, this invention first achieves preliminary separation of caffeic acid esters and scutellarin, followed by further purification and separation based on the properties of the two types of substances. Specifically, this invention uses ethanol-water solutions of different concentrations to extract caffeic acid esters stepwise, and uses macroporous and microporous resins for preliminary separation of the caffeic acid esters. Scutellarin is then preliminarily separated through acid-base treatment. Finally, high-purity scutellarin, 3,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and scutellarin are obtained through reversed-phase industrial chromatography. This invention achieves the extraction and separation of multiple active ingredients from *Erigeron breviscapus*, and all solvents used in the extraction and separation process are recyclable, resulting in low cost.

The application discloses application of 1,5-dicaffeoylquinic acid in prevention and / or treatment of non-alcoholic fatty liver disease and weight loss and blood lipid reduction, and belongs to the technical field of biological medicine. The application first proposes application of 1,5-dicaffeoylquinic acid in preparation of a medicine for preventing and / or treating metabolic related fatty diseases. In-vivo and in-vitro experimental results show that after 1,5-dicaffeoylquinic acid is used in an in-vitro and in-vivo NAFLD model, the weight can be reduced, liver function and blood lipid abnormality, sugar metabolism abnormality and lipid accumulation can be relieved; the 1,5-dicaffeoylquinic acid can be used for preparing a medicine for preventing or treating NAFLD, obesity and blood lipid reduction, and the new use of the 1,5-dicaffeoylquinic acid in resisting NAFLD is confirmed, so that the 1,5-dicaffeoylquinic acid is expected to be developed into a new type of NAFLD resisting medicine, and has a wide market prospect.

The present application belongs to the technical field of quality detection of traditional Chinese medicinal materials, and particularly relates to a method for quantitatively analyzing effective components of Xiaochaihu medicinal materials. The method comprises the following steps: a, preparation of a control solution: precisely take new chlorogenic acid, chlorogenic acid, cryptochlorogenic acid, rutin, 3,5-O-dicaffeoylquinic acid, quercitrin and 4,5-O-dicaffeoylquinic acid control samples, and add methanol to prepare a mixed control solution; b, preparation of a test solution: crush Xiaochaihu medicinal materials, add a methanol solution for extraction, and filter to obtain the test solution; and c, determination: precisely take the control solution and the test solution, inject them into an ultra-high performance liquid chromatograph, and determine the content by using an external standard method. The method can simultaneously detect and analyze the content of seven chemical components in Xiaochaihu medicinal materials, has good linearity, repeatability, stability and recovery rate, and can effectively control the quality of Xiaochaihu medicinal materials.

The present application relates to the technical field of traditional Chinese medicine detection, and specifically provides a characteristic spectrum construction method of Herba Centipedae and its preparation. A specific elution procedure is obtained through a large number of experiments by using octadecylsilane bonded silica gel as a filler and a mobile phase including methanol and an acid-containing aqueous solution for gradient elution, 13 or more common characteristic peaks are obtained, and effective separation of characteristic peaks including neochlorogenic acid, caffeic acid, chlorogenic acid, cryptochlorogenic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, big pothos glycoside and thymotin lactone ketone is achieved, the peak shape is good, the baseline is smooth, the determined components can be completely separated, the detection time is short, and the method provides a basis for quality detection and control of Herba Centipedae and its preparation, can fully reflect the integrity and characteristics of Herba Centipedae and its preparation, and is simple to operate and applicable to quality control of different preparation types of Herba Centipedae.

The application discloses a characteristic chromatogram construction method and identification method of Senecae Scandentae, its decoction pieces, standard decoction and formula granules, and relates to the technical field of traditional Chinese medicine identification. The characteristic chromatogram construction method comprises the following steps: methanol is used to extract the to-be-detected sample to obtain a test sample solution; methanol is used to dissolve 5-caffeoylquinic acid, chlorogenic acid, caffeic acid, 4-caffeoylquinic acid, rutin, hyperoside, isoquercitrin and 4,5-dicaffeoylquinic acid as a control sample solution; and a liquid chromatograph is used for determination. The chromatographic column of the liquid chromatograph uses phenyl-methyl polysiloxane as a stationary phase, acetonitrile as a mobile phase A and 0.05vol%-0.3vol% methanoic acid aqueous solution as a mobile phase B for gradient elution. The characteristic chromatogram constructed by the application is rich in information and can quickly and comprehensively reflect the quality of Senecae Scandentae, its decoction pieces, standard decoction and formula granules.

A steviol glycoside solubility enhancer may include a monocaffeoylquinic (MCQ) component that includes at least one compound selected from the group consisting of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, and salts thereof; and a dicaffeoylquinic (DCQ) component that includes at least one compound selected from the group consisting of 1,3-dicaffeoylquinic acid, 1,4-dicaffeoylquinic acid, 1,5-dicaffeoylquinic acid, 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, 4,5-dicaffeoylquinic acid, and salts thereof. In one suitable implementation, the MCQ component and the DCQ component together comprise more than 50% (wt), preferably more than 60% (wt), more than 70% (wt), more than 80% (wt), more than 90% (wt), or more than 95% (wt) of the steviol glycoside solubility enhancer.

A method for making a caffeoylquinic composition from a botanical source is disclosed. The method may include chromatographing an extract of biomass on an ion exchange stationary phase and obtaining an eluent comprising a caffeoylquinic composition. The biomass may be stevia or yerba mate, for example. The caffeoylquinic composition includes one or more of monocaffeoylquinic acid, dicaffeoylquinic acid, and salts of the foregoing.

The invention belongs to the technical field of biological medicines, and particularly relates to application of 1, 3-dicaffeoylquinic acid (1, 3-DCQA) in preparation of a medicine for improving glucose and lipid metabolism disorder. The invention discloses application of 1, 3-DCQA in nitraria tangutorum bobr to preparation of a medicine for improving glucose and lipid metabolism disorder, and proves that the 1, 3-DCQA is inhibited by glycosidase (sucrase and maltase) of the 1, 3-DCQA, so that intestinal flora is changed, then short-chain fatty acid acetic acid secretion is promoted, acetic acid is used as a signal molecule to activate a GPR43 signal channel, and further insulin sensitivity is improved. The effect of regulating glycolipid metabolism is achieved. The invention not only provides a solid experimental basis for medicinal development of 1, 3-DCQA in Nitraria tangutorum Bobr, but also provides a brand new action target and direction for research and development of novel medicaments for treating glucose and lipid metabolism disorders, and has important theoretical significance and wide clinical transformation prospects.